G
140.44
4.12 (3.02%)
| 前收盘价格 | 136.32 |
| 收盘价格 | 137.09 |
| 成交量 | 261,934 |
| 平均成交量 (3个月) | 512,998 |
| 市值 | 4,059,360,768 |
| 市盈率 (P/E TTM) | 1,276.73 |
| 预期市盈率 (P/E Forward) | 156.25 |
| 价格/销量 (P/S) | 6.78 |
| 股市价格/股市净资产 (P/B) | 9.52 |
| 52周波幅 | |
| 利润日期 | 28 Oct 2025 |
| 营业毛利率 | -11.69% |
| 营业利益率 (TTM) | -5.22% |
| 稀释每股收益 (EPS TTM) | -1.39 |
| 季度收入增长率 (YOY) | 39.60% |
| 总债务/股东权益 (D/E MRQ) | 44.61% |
| 流动比率 (MRQ) | 3.25 |
| 营业现金流 (OCF TTM) | -1.90 M |
| 杠杆自由现金流 (LFCF TTM) | 17.79 M |
| 资产报酬率 (ROA TTM) | -1.84% |
| 股东权益报酬率 (ROE TTM) | -16.61% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Diagnostics & Research (US) | 看涨 | 看涨 |
| Diagnostics & Research (全球的) | 看涨 | 看涨 | |
| 股票 | GeneDx Holdings Corp. | 看涨 | 看涨 |
AIStockmoo 评分
-0.5
| 分析师共识 | 3.0 |
| 内部交易活动 | NA |
| 价格波动 | -4.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -0.5 |
| 平均 | -0.50 |
|
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world’s substantial rare disease data sets. |
|
| 部门 | Healthcare |
| 行业 | Diagnostics & Research |
| 投资方式 | Small Core |
| 内部持股比例 | 12.56% |
| 机构持股比例 | 102.71% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 200.00 (BTIG, 42.41%) | 购买 |
| 中 | 170.00 (21.05%) | |
| 低 | 155.00 (Wells Fargo, 10.37%) | 保留 |
| 平均值 | 175.00 (24.61%) | |
| 总计 | 2 购买, 1 保留 | |
| 平均价格@调整类型 | 147.43 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Canaccord Genuity | 22 Dec 2025 | 170.00 (21.05%) | 购买 | 140.17 |
| Wells Fargo | 15 Dec 2025 | 155.00 (10.37%) | 保留 | 150.61 |
| 04 Nov 2025 | 140.00 (-0.31%) | 保留 | 139.49 | |
| BTIG | 12 Dec 2025 | 200.00 (42.41%) | 购买 | 151.51 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合